Effects of hydrocortisone on acute beta-blocker and histamine induced bronchoconstriction Source: Annual Congress 2011 - Asthma management and response Year: 2011
Protective effect of inhaled iloprost on exercise-induced bronchoconstriction Source: Eur Respir J 2004; 24: Suppl. 48, 443s Year: 2004
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Paradoxical bronchoconstriction after administration of beta-2 agonist bronchodilators in COPD patients Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005
α1 -adrenoceptor antagonism does not modify the pulmonary vasoconstrictor effect of dexfenfluramine in the rat Source: Eur Respir J 2001; 18: Suppl. 33, 491s Year: 2001
Protective effect of inhaled anticholinergic drugs in the methacholine test Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002
Bronchodilator tolerance: the impact of increasing bronchoconstriction Source: Eur Respir J 2003; 21: 810-815 Year: 2003
PDE 3/4 inhibition prolonges pulmonary vasodilatory response to inhaled iloprost Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Source: Eur Respir J 2001; 17: 368-373 Year: 2001
Intracerebroventricular serotonin reduces the degree of acute hypoxic ventilatory depression in peripherally chemodenervated rabbits Source: Eur Respir J 2007; 30: Suppl. 51, 597s Year: 2007
Arrhythmogenic and chronotropic effects of bronchodilator drugs on human cardiomyocytes Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
Comparison of treatments with nebulised salbutamol and epinephrine in acute bronchiolitis Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Antibacterial effect of lidocaine, thrombin, and epinephrine Source: Eur Respir J 2006; 28: Suppl. 50, 732s Year: 2006
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008